NEW BRUNSWICK, N.J.,
Oct. 18, 2016 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced sales of
$17.8 billion for the third quarter
of 2016, an increase of 4.2% as compared to the third quarter of
2015. Operational sales results increased 4.3% and the negative
impact of currency was 0.1%. Domestic sales increased 6.7%.
International sales increased 1.5%, reflecting operational growth
of 1.7% and a negative currency impact of 0.2%. Excluding the net
impact of acquisitions, divestitures and hepatitis C sales, on an
operational basis, worldwide sales increased 5.9%, domestic sales
increased 7.3% and international sales increased 4.2%.*
Operations in Venezuela negatively
impacted worldwide operational sales growth by 30 basis points, and
international sales growth by 70 basis points.
Net earnings and diluted earnings per share for the third
quarter of 2016 were $4.3 billion and
$1.53, respectively. Third quarter
2016 net earnings included after-tax intangible amortization
expense of approximately $0.2 billion
and a charge for after-tax special items of approximately
$0.2 billion. Third quarter 2015 net
earnings included after-tax intangible amortization expense of
approximately $0.4 billion and a
charge for after-tax special items of approximately $0.4 billion. Excluding after-tax intangible
amortization expense and special items, adjusted net earnings for
the current quarter were $4.7 billion
and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%,
respectively, as compared to the same period in 2015.*
On an operational basis, adjusted diluted earnings per share also
increased 12.8%.* A reconciliation of non-GAAP financial
measures is included as an accompanying schedule.
"Our third-quarter results reflect the success of our new
product launches and the strength of our core businesses, driven by
strong growth in our Pharmaceuticals business. With a number of
regulatory approvals, several new drug application submissions and
new breakthrough therapy designations from the FDA, we are
increasingly confident in our pipeline expectation of filing 10 new
pharmaceutical products between 2015 and 2019, each with revenue
potential over $1 billion," said
Alex Gorsky, Chairman and Chief
Executive Officer. "Our broad-based business model, strategic
investments and talented colleagues position us well for continued
leadership in health care."
The Company maintained its sales guidance for the full-year 2016
of $71.5 billion to $72.2 billion.
Additionally, the Company increased its adjusted earnings guidance
for full-year 2016 to $6.68 - $6.73
per share.*
Worldwide Consumer sales of $3.3
billion for the third quarter 2016 represented a decrease of
1.6% versus the prior year, consisting of an operational increase
of 0.1% and a negative impact from currency of 1.7%. Domestic sales
increased 1.1%; international sales decreased 3.3%, which reflected
an operational decrease of 0.6% and a negative currency impact of
2.7%. Excluding the net impact of acquisitions and divestitures, on
an operational basis, worldwide sales decreased 0.4%, domestic
sales decreased 1.5% and international sales increased
0.3%*. Operations in Venezuela negatively impacted worldwide
Consumer operational sales growth by 110 basis points and
international sales growth by 180 basis points.
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were negatively impacted by lower
trade inventory levels, primarily in the U.S. Positive contributors
to Consumer operational sales results included
LISTERINE® oral care products; AVEENO® skin
care products and digestive health products and international
smoking aids in over-the-counter products.
Worldwide Pharmaceutical sales of $8.4
billion for the third quarter 2016 represented an increase
of 9.2% versus the prior year with an operational increase of 9.0%
and a positive impact from currency of 0.2%. Domestic sales
increased 11.8%; international sales increased 5.4%, which
reflected an operational increase of 5.0% and a positive currency
impact of 0.4%. Excluding the net impact of acquisitions,
divestitures and hepatitis C sales, on an operational basis,
worldwide sales increased 10.7%, domestic sales increased 13.0% and
international sales increased 7.0%.*
Worldwide operational results, excluding the net impact of
acquisitions, divestitures and hepatitis C sales, were driven by
new products and the strength of core products. Strong growth in
new products include IMBRUVICA® (ibrutinib), an oral,
once-daily therapy approved for use in treating certain B-cell
malignancies, a type of blood or lymph node cancer;
DARZALEX® (daratumumab), for the treatment of patients
with multiple myeloma; and XARELTO® (rivaroxaban), an
oral anticoagulant.
Additional contributors to operational sales growth included
STELARA® (ustekinumab), REMICADE®
(infliximab) and SIMPONI®/SIMPONI ARIA®
(golimumab), biologics approved for the treatment of a number of
immune-mediated inflammatory diseases; and INVEGA®
SUSTENNA®/XEPLION®/TRINZA®
(paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults.
During the quarter, the U.S. Food and Drug Administration (FDA)
approved INVOKAMET® XR (canagliflozin/metformin HCl
extended-release) for first-line treatment of adults with type 2
diabetes, and STELARA® (ustekinumab) for the treatment
of adults with moderately to severely active Crohn's disease. The
Committee for Medicinal Products for Human Use issued a positive
opinion recommending approval of STELARA® for the
treatment of adults with moderately to severely active Crohn's
disease.
Additionally, regulatory applications for approval were
submitted to the FDA and European Medicines Agency (EMA) for
DARZALEX® in combination with standard-of-care regimens
for patients with multiple myeloma who have received at least one
prior therapy. DARZALEX® also received
Breakthrough Therapy Designation from the FDA for this pending
indication. The FDA also granted Breakthrough Therapy Designation
to esketamine for major depressive disorder with imminent risk for
suicide. Regulatory applications for approval were also
submitted to the FDA for sirukumab in rheumatoid arthritis, and to
EMA for a darunavir-based single tablet regimen for the treatment
of HIV-1.
Worldwide Medical Devices sales of $6.2
billion for the third quarter 2016 represented an increase
of 1.1% versus the prior year consisting of an operational increase
of 0.7% and a positive currency impact of 0.4%. Domestic sales
increased 1.4%; international sales increased 0.7%, which reflected
an operational decline of 0.2% and a positive currency impact of
0.9%. Excluding the net impact of acquisitions and divestitures, on
an operational basis, worldwide sales increased 3.1%, domestic
sales increased 2.3% and international sales increased
3.9%.*
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by electrophysiology
products in the Cardiovascular business; endocutters and energy in
the Advanced Surgery business; ACUVUE® contact lenses in
the Vision Care business; and joint reconstruction and trauma
products in the Orthopaedics business.
During the quarter, a definitive agreement was announced to
acquire Abbott Medical Optics, a wholly-owned subsidiary of Abbott
Laboratories, for $4.325 billion in
cash. Acclarent announced the U.S. launch of ACCLARENT
AERA™, the first balloon dilation intervention approved
by the FDA for Eustachian Tube Dysfunction.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites
the people of Johnson & Johnson. We embrace research and
science - bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
126,900 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
* Operational sales growth excluding the net impact
of acquisitions, divestitures and hepatitis C sales, as well as
adjusted net earnings, adjusted diluted earnings per share and
operational adjusted diluted earnings per share excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures, reconciliations
of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying
financial schedules of the earnings release and the Investor
Relations section of the company's website at www.investor.jnj.com.
Johnson & Johnson does not provide GAAP financial measures on a
forward-looking basis because the company is unable to predict with
reasonable certainty the ultimate outcome of legal proceedings,
unusual gains and losses, acquisition-related expenses and purchase
accounting fair value adjustments without unreasonable effort.
These items are uncertain, depend on various factors, and could be
material to Johnson & Johnson's results computed in accordance
with GAAP.
Johnson & Johnson will conduct a conference call with
investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast
of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at
www.investor.jnj.com. A replay and podcast will be available
approximately two hours after the live webcast by visiting
www.investor.jnj.com.
Copies of the financial schedules accompanying this press
release are available at www.investor.jnj.com/historical-sales.cfm.
These schedules include supplementary sales data, a condensed
consolidated statement of earnings, reconciliations of non-GAAP
financial measures, and sales of key products/franchises.
Additional information on Johnson & Johnson, including adjusted
income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today's earnings
call presentation can be found on the company's website at
www.investor.jnj.com.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to, economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the company to successfully
execute strategic plans, including restructuring plans; market
conditions and the possibility that the on-going share repurchase
program may be delayed, suspended or discontinued; the impact of
business combinations and divestitures; significant adverse
litigation or government action, including related to product
liability claims; changes to applicable laws and regulations,
including tax laws and global health care reforms; trends toward
health care cost containment; changes in behavior and spending
patterns or financial distress of purchasers of health care
products and services; financial instability of international
economies and legal systems and sovereign risk; manufacturing
difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or
regulatory action; increased scrutiny of the health care industry
by government agencies; and the potential failure to meet
obligations in compliance agreements with government bodies. A
further list and description of these risks, uncertainties and
other factors can be found in Johnson & Johnson's Annual Report
on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto,
and the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.investor.jnj.com, or on request from Johnson
& Johnson. Any forward-looking statement made in this release
speaks only as of the date of this release. Johnson & Johnson
does not undertake to update any forward-looking statement as a
result of new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
|
Currency
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,291
|
|
1,277
|
|
1.1
|
%
|
1.1
|
|
-
|
|
$
4,033
|
|
3,991
|
|
1.1
|
%
|
1.1
|
|
-
|
International
|
1,970
|
|
2,037
|
|
(3.3)
|
|
(0.6)
|
|
(2.7)
|
|
5,842
|
|
6,196
|
|
(5.7)
|
|
0.1
|
|
(5.8)
|
|
3,261
|
|
3,314
|
|
(1.6)
|
|
0.1
|
|
(1.7)
|
|
9,875
|
|
10,187
|
|
(3.1)
|
|
0.4
|
|
(3.5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
5,042
|
|
4,509
|
|
11.8
|
|
11.8
|
|
-
|
|
15,123
|
|
13,423
|
|
12.7
|
|
12.7
|
|
-
|
International
|
3,358
|
|
3,185
|
|
5.4
|
|
5.0
|
|
0.4
|
|
10,109
|
|
9,943
|
|
1.7
|
|
4.2
|
|
(2.5)
|
|
8,400
|
|
7,694
|
|
9.2
|
|
9.0
|
|
0.2
|
|
25,232
|
|
23,366
|
|
8.0
|
|
9.1
|
|
(1.1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,048
|
|
3,005
|
|
1.4
|
|
1.4
|
|
-
|
|
9,118
|
|
8,980
|
|
1.5
|
|
1.5
|
|
-
|
International
|
3,111
|
|
3,089
|
|
0.7
|
|
(0.2)
|
|
0.9
|
|
9,559
|
|
9,730
|
|
(1.8)
|
|
0.5
|
|
(2.3)
|
|
6,159
|
|
6,094
|
|
1.1
|
|
0.7
|
|
0.4
|
|
18,677
|
|
18,710
|
|
(0.2)
|
|
1.0
|
|
(1.2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
9,381
|
|
8,791
|
|
6.7
|
|
6.7
|
|
-
|
|
28,274
|
|
26,394
|
|
7.1
|
|
7.1
|
|
-
|
International
|
8,439
|
|
8,311
|
|
1.5
|
|
1.7
|
|
(0.2)
|
|
25,510
|
|
25,869
|
|
(1.4)
|
|
1.8
|
|
(3.2)
|
Worldwide
|
$
17,820
|
|
17,102
|
|
4.2
|
%
|
4.3
|
|
(0.1)
|
|
$
53,784
|
|
52,263
|
|
2.9
|
%
|
4.5
|
|
(1.6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
|
Currency
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
9,381
|
|
8,791
|
|
6.7
|
%
|
6.7
|
|
-
|
|
$
28,274
|
|
26,394
|
|
7.1
|
%
|
7.1
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
3,832
|
|
3,802
|
|
0.8
|
|
3.2
|
|
(2.4)
|
|
11,769
|
|
11,993
|
|
(1.9)
|
|
0.5
|
|
(2.4)
|
Western Hemisphere
excluding U.S.
|
1,396
|
|
1,463
|
|
(4.6)
|
|
(1.3)
|
|
(3.3)
|
|
4,269
|
|
4,603
|
|
(7.3)
|
|
4.4
|
|
(11.7)
|
Asia-Pacific,
Africa
|
3,211
|
|
3,046
|
|
5.4
|
|
1.4
|
|
4.0
|
|
9,472
|
|
9,273
|
|
2.1
|
|
2.1
|
|
0.0
|
International
|
8,439
|
|
8,311
|
|
1.5
|
|
1.7
|
|
(0.2)
|
|
25,510
|
|
25,869
|
|
(1.4)
|
|
1.8
|
|
(3.2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
17,820
|
|
17,102
|
|
4.2
|
%
|
4.3
|
|
(0.1)
|
|
$
53,784
|
|
52,263
|
|
2.9
|
%
|
4.5
|
|
(1.6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
THIRD
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
17,820
|
|
100.0
|
|
$
17,102
|
|
100.0
|
|
4.2
|
Cost of products
sold
|
5,486
|
|
30.8
|
|
5,224
|
|
30.5
|
|
5.0
|
Selling, marketing
and administrative expenses
|
4,772
|
|
26.8
|
|
5,081
|
|
29.7
|
|
(6.1)
|
Research and
development expense
|
2,178
|
|
12.2
|
|
2,154
|
|
12.6
|
|
1.1
|
In-process
research and development
|
-
|
|
-
|
|
10
|
|
0.1
|
|
|
Interest (income)
expense, net
|
95
|
|
0.5
|
|
91
|
|
0.5
|
|
|
Other (income)
expense, net
|
(54)
|
|
(0.2)
|
|
420
|
|
2.5
|
|
|
Restructuring
|
62
|
|
0.3
|
|
-
|
|
-
|
|
|
Earnings before
provision for taxes on income
|
5,281
|
|
29.6
|
|
4,122
|
|
24.1
|
|
28.1
|
Provision for
taxes on income
|
1,009
|
|
5.6
|
|
764
|
|
4.5
|
|
32.1
|
Net
earnings
|
$
4,272
|
|
24.0
|
|
$
3,358
|
|
19.6
|
|
27.2
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.53
|
|
|
|
$
1.20
|
|
|
|
27.5
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,785.4
|
|
|
|
2,807.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
19.1
|
%
|
|
|
18.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
5,831
|
|
32.7
|
|
$
5,212
|
|
30.5
|
|
11.9
|
Net
earnings
|
$
4,683
|
|
26.3
|
|
$
4,172
|
|
24.4
|
|
12.2
|
Net earnings per
share (Diluted)
|
$
1.68
|
|
|
|
$
1.49
|
|
|
|
12.8
|
Effective tax
rate
|
19.7
|
%
|
|
|
20.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
NINE
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
53,784
|
|
100.0
|
|
$
52,263
|
|
100.0
|
|
2.9
|
Cost of products
sold
|
16,151
|
|
30.0
|
|
15,863
|
|
30.4
|
|
1.8
|
Selling, marketing
and administrative expenses
|
14,636
|
|
27.2
|
|
15,312
|
|
29.3
|
|
(4.4)
|
Research and
development expense
|
6,455
|
|
12.0
|
|
6,182
|
|
11.8
|
|
4.4
|
In-process
research and development
|
29
|
|
0.1
|
|
10
|
|
0.0
|
|
|
Interest (income)
expense, net
|
274
|
|
0.5
|
|
317
|
|
0.6
|
|
|
Other (income)
expense, net
|
464
|
|
0.9
|
|
(859)
|
|
(1.6)
|
|
|
Restructuring
|
296
|
|
0.5
|
|
-
|
|
-
|
|
|
Earnings before
provision for taxes on income
|
15,479
|
|
28.8
|
|
15,438
|
|
29.5
|
|
0.3
|
Provision for
taxes on income
|
2,753
|
|
5.1
|
|
3,244
|
|
6.2
|
|
(15.1)
|
Net
earnings
|
$
12,726
|
|
23.7
|
|
$
12,194
|
|
23.3
|
|
4.4
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
4.55
|
|
|
|
$
4.33
|
|
|
|
5.1
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,796.6
|
|
|
|
2,817.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
17.8
|
%
|
|
|
21.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
17,656
|
|
32.8
|
|
$
17,090
|
|
32.7
|
|
3.3
|
Net
earnings
|
$
14,403
|
|
26.8
|
|
$
13,402
|
|
25.6
|
|
7.5
|
Net earnings per
share (Diluted)
|
$
5.15
|
|
|
|
$
4.76
|
|
|
|
8.2
|
Effective tax
rate
|
18.4
|
%
|
|
|
21.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third
Quarter
|
|
% Incr. /
|
|
|
Nine Months
YTD
|
|
% Incr. /
|
|
(Dollars in
Millions Except Per Share Data)
|
2016
|
|
2015
|
|
(Decr.)
|
|
|
2016
|
|
2015
|
|
(Decr.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as reported
|
$ 5,281
|
|
4,122
|
|
28.1
|
%
|
|
$ 15,479
|
|
15,438
|
|
0.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
319
|
|
639
|
|
|
|
|
927
|
|
1,269
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
(1)
|
109
|
|
-
|
|
|
|
|
387
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
55
|
|
409
|
|
|
|
|
721
|
|
141
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
-
|
|
-
|
|
|
|
|
-
|
|
148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
-
|
|
10
|
|
|
|
|
29
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
67
|
|
32
|
|
|
|
|
113
|
|
84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as adjusted
|
$ 5,831
|
|
5,212
|
|
11.9
|
%
|
|
$ 17,656
|
|
17,090
|
|
3.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
reported
|
$ 4,272
|
|
3,358
|
|
27.2
|
%
|
|
$ 12,726
|
|
12,194
|
|
4.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
236
|
|
437
|
|
|
|
|
679
|
|
893
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
|
76
|
|
-
|
|
|
|
|
293
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
46
|
|
348
|
|
|
|
|
595
|
|
118
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
-
|
|
-
|
|
|
|
|
-
|
|
130
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
-
|
|
6
|
|
|
|
|
23
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
53
|
|
23
|
|
|
|
|
87
|
|
61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
adjusted
|
$ 4,683
|
|
4,172
|
|
12.2
|
%
|
|
$ 14,403
|
|
13,402
|
|
7.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as reported
|
$
1.53
|
|
1.20
|
|
27.5
|
%
|
|
$
4.55
|
|
4.33
|
|
5.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
0.08
|
|
0.16
|
|
|
|
|
0.24
|
|
0.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
|
0.03
|
|
-
|
|
|
|
|
0.11
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
0.02
|
|
0.12
|
|
|
|
|
0.21
|
|
0.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
-
|
|
-
|
|
|
|
|
-
|
|
0.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
-
|
|
-
|
|
|
|
|
0.01
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
0.02
|
|
0.01
|
|
|
|
|
0.03
|
|
0.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as adjusted
|
$
1.68
|
|
1.49
|
|
12.8
|
%
|
|
$
5.15
|
|
4.76
|
|
8.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at 2014 foreign currency
exchange rates
|
|
|
1.63
|
|
|
|
|
|
|
5.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of currency at
2015 foreign currency exchange rates
|
$
-
|
|
(0.14)
|
|
|
|
|
$
0.04
|
|
(0.46)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at 2015 foreign currency
exchange rates
|
$
1.68
|
|
1.49
|
|
12.8
|
%
|
|
$
5.19
|
|
4.76
|
|
9.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Includes $3M recorded in cost of products sold and $44M recorded in
other (income) expense for the third quarter.
|
Includes $27M recorded in cost of products sold and $64M recorded
in other (income) expense for nine months YTD.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions, Divestitures, and Hepatitis C
Sales(1)
|
THIRD
QUARTER 2016 ACTUAL vs. 2015 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational
%(2)
|
WW As
Reported:
|
|
0.1%
|
|
9.0%
|
|
0.7%
|
|
4.3%
|
U.S.
|
|
1.1%
|
|
11.8%
|
|
1.4%
|
|
6.7%
|
International
|
|
(0.6)%
|
|
5.0%
|
|
(0.2)%
|
|
1.7%
|
|
|
|
|
|
|
|
|
|
Wound
Care/Other
|
|
|
|
|
|
|
|
|
SPLENDA®
|
|
2.1
|
|
|
|
|
|
0.4
|
U.S.
|
|
4.0
|
|
|
|
|
|
0.6
|
International
|
|
1.0
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Cardiovascular
|
|
|
|
|
|
|
|
|
Cordis
|
|
|
|
|
|
2.3
|
|
0.9
|
U.S.
|
|
|
|
|
|
1.1
|
|
0.4
|
International
|
|
|
|
|
|
3.7
|
|
1.4
|
|
|
|
|
|
|
|
|
|
Skin
Care
|
|
(2.3)
|
|
|
|
|
|
|
Vogue
|
|
(5.8)
|
|
|
|
|
|
(0.4)
|
U.S.
|
|
0.0
|
|
|
|
|
|
(0.8)
|
International
|
|
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
Other
Neuroscience
|
|
|
|
|
|
|
|
|
Controlled
Substance Raw Material and API Business
|
|
|
|
0.7
|
|
|
|
0.3
|
U.S.
|
|
|
|
0.9
|
|
|
|
0.4
|
International
|
|
|
|
0.4
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
(0.3)
|
|
0.0
|
|
0.1
|
|
0.0
|
U.S.
|
|
(0.8)
|
|
0.0
|
|
(0.2)
|
|
(0.2)
|
International
|
|
(0.1)
|
|
0.0
|
|
0.4
|
|
0.2
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
(0.4)%
|
|
9.7%
|
|
3.1%
|
|
5.5%
|
U.S.
|
|
(1.5)%
|
|
12.7%
|
|
2.3%
|
|
7.1%
|
International
|
|
0.3%
|
|
5.4%
|
|
3.9%
|
|
3.6%
|
|
|
|
|
|
|
|
|
|
Hepatitis
C
|
|
|
|
1.0
|
|
|
|
0.4
|
U.S.
|
|
|
|
0.3
|
|
|
|
0.2
|
International
|
|
|
|
1.6
|
|
|
|
0.6
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Hepatitis C only
|
|
|
|
10.0%
|
|
|
|
4.7%
|
U.S.
|
|
|
|
12.1%
|
|
|
|
6.9%
|
International
|
|
|
|
6.6%
|
|
|
|
2.3%
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions, Divestitures and Hepatitis C
|
|
(0.4)%
|
|
10.7%
|
|
3.1%
|
|
5.9%
|
U.S.
|
|
(1.5)%
|
|
13.0%
|
|
2.3%
|
|
7.3%
|
International
|
|
0.3%
|
|
7.0%
|
|
3.9%
|
|
4.2%
|
|
|
|
|
|
|
|
|
|
(1)
Hepatitis C products include
OLYSIO®/SOVRIAD®and
INCIVO®
|
|
|
|
(2)
Operational growth excludes the effect of translational
currency
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions, Divestitures, and Hepatitis C
Sales(1)
|
NINE MONTHS
2016 ACTUAL vs. 2015 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational
%(2)
|
WW As
Reported:
|
|
0.4%
|
|
9.1%
|
|
1.0%
|
|
4.5%
|
U.S.
|
|
1.1%
|
|
12.7%
|
|
1.5%
|
|
7.1%
|
International
|
|
0.1%
|
|
4.2%
|
|
0.5%
|
|
1.8%
|
|
|
|
|
|
|
|
|
|
Wound
Care/Other
|
|
|
|
|
|
|
|
|
SPLENDA®
|
|
2.2
|
|
|
|
|
|
0.4
|
U.S.
|
|
4.3
|
|
|
|
|
|
0.7
|
International
|
|
0.9
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Cardiovascular
|
|
|
|
|
|
|
|
|
Cordis
|
|
|
|
|
|
2.4
|
|
0.9
|
U.S.
|
|
|
|
|
|
1.1
|
|
0.4
|
International
|
|
|
|
|
|
3.5
|
|
1.3
|
|
|
|
|
|
|
|
|
|
Skin
Care
|
|
(0.7)
|
|
|
|
|
|
|
Vogue
|
|
(1.9)
|
|
|
|
|
|
(0.1)
|
U.S.
|
|
0.0
|
|
|
|
|
|
(0.3)
|
International
|
|
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
(0.1)
|
|
0.4
|
|
0.0
|
|
0.1
|
U.S.
|
|
(0.3)
|
|
0.7
|
|
(0.1)
|
|
0.2
|
International
|
|
0.0
|
|
0.0
|
|
0.1
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
1.8%
|
|
9.5%
|
|
3.4%
|
|
5.8%
|
U.S.
|
|
3.2%
|
|
13.4%
|
|
2.5%
|
|
8.1%
|
International
|
|
1.0%
|
|
4.2%
|
|
4.1%
|
|
3.4%
|
|
|
|
|
|
|
|
|
|
Hepatitis
C
|
|
|
|
2.4
|
|
|
|
1.1
|
U.S.
|
|
|
|
1.1
|
|
|
|
0.6
|
International
|
|
|
|
4.2
|
|
|
|
1.6
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Hepatitis C only
|
|
|
|
11.5%
|
|
|
|
5.6%
|
U.S.
|
|
|
|
13.8%
|
|
|
|
7.7%
|
International
|
|
|
|
8.4%
|
|
|
|
3.4%
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions, Divestitures, and Hepatitis C
|
|
1.8%
|
|
11.9%
|
|
3.4%
|
|
6.9%
|
U.S.
|
|
3.2%
|
|
14.5%
|
|
2.5%
|
|
8.7%
|
International
|
|
1.0%
|
|
8.4%
|
|
4.1%
|
|
5.0%
|
|
|
|
|
|
|
|
|
|
(1)
Hepatitis C products include
OLYSIO®/SOVRIAD®and
INCIVO®
|
|
|
|
|
(2)
Operational growth excludes the effect of translational
currency
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER SEGMENT
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
96
|
|
103
|
-6.8%
|
-6.8%
|
-
|
|
|
$
293
|
|
$
318
|
-7.9%
|
-7.9%
|
-
|
Intl
|
|
370
|
|
403
|
-8.2%
|
-5.3%
|
-2.9%
|
|
|
1,124
|
|
1,242
|
-9.5%
|
-2.5%
|
-7.0%
|
WW
|
|
466
|
|
506
|
-7.9%
|
-5.6%
|
-2.3%
|
|
|
1,417
|
|
1,560
|
-9.2%
|
-3.6%
|
-5.6%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
156
|
|
154
|
1.3%
|
1.3%
|
-
|
|
|
485
|
|
459
|
5.7%
|
5.7%
|
-
|
Intl
|
|
227
|
|
224
|
1.3%
|
3.1%
|
-1.8%
|
|
|
686
|
|
713
|
-3.8%
|
1.8%
|
-5.6%
|
WW
|
|
383
|
|
378
|
1.3%
|
2.3%
|
-1.0%
|
|
|
1,171
|
|
1,172
|
-0.1%
|
3.3%
|
-3.4%
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
380
|
|
383
|
-0.8%
|
-0.8%
|
-
|
|
|
1,230
|
|
1,154
|
6.6%
|
6.6%
|
-
|
Intl
|
|
584
|
|
580
|
0.7%
|
3.5%
|
-2.8%
|
|
|
1,761
|
|
1,776
|
-0.8%
|
4.2%
|
-5.0%
|
WW
|
|
964
|
|
963
|
0.1%
|
1.8%
|
-1.7%
|
|
|
2,991
|
|
2,930
|
2.1%
|
5.1%
|
-3.0%
|
SKIN CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
517
|
|
435
|
18.9%
|
18.9%
|
-
|
|
|
1,560
|
|
1,418
|
10.0%
|
10.0%
|
-
|
Intl
|
|
438
|
|
428
|
2.3%
|
5.3%
|
-3.0%
|
|
|
1,210
|
|
1,242
|
-2.6%
|
2.7%
|
-5.3%
|
WW
|
|
955
|
|
863
|
10.7%
|
12.2%
|
-1.5%
|
|
|
2,770
|
|
2,660
|
4.1%
|
6.6%
|
-2.5%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3
|
|
6
|
-50.0%
|
-50.0%
|
-
|
|
|
16
|
|
19
|
-15.8%
|
-15.8%
|
-
|
Intl
|
|
266
|
|
304
|
-12.5%
|
-9.1%
|
-3.4%
|
|
|
787
|
|
898
|
-12.4%
|
-5.1%
|
-7.3%
|
WW
|
|
269
|
|
310
|
-13.2%
|
-9.9%
|
-3.3%
|
|
|
803
|
|
917
|
-12.4%
|
-5.3%
|
-7.1%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
139
|
|
196
|
-29.1%
|
-29.1%
|
-
|
|
|
449
|
|
623
|
-27.9%
|
-27.9%
|
-
|
Intl
|
|
85
|
|
98
|
-13.3%
|
-13.2%
|
-0.1%
|
|
|
274
|
|
325
|
-15.7%
|
-12.0%
|
-3.7%
|
WW
|
|
224
|
|
294
|
-23.8%
|
-23.8%
|
0.0%
|
|
|
723
|
|
948
|
-23.7%
|
-22.4%
|
-1.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
CONSUMER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,291
|
|
1,277
|
1.1%
|
1.1%
|
-
|
|
|
4,033
|
|
3,991
|
1.1%
|
1.1%
|
-
|
Intl
|
|
1,970
|
|
2,037
|
-3.3%
|
-0.6%
|
-2.7%
|
|
|
5,842
|
|
6,196
|
-5.7%
|
0.1%
|
-5.8%
|
WW
|
|
$
3,261
|
|
3,314
|
-1.6%
|
0.1%
|
-1.7%
|
|
|
$
9,875
|
|
10,187
|
-3.1%
|
0.4%
|
-3.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
PHARMACEUTICAL
SEGMENT (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,294
|
|
1,910
|
20.1%
|
20.1%
|
-
|
|
|
$
6,689
|
|
5,541
|
20.7%
|
20.7%
|
-
|
Intl
|
|
790
|
|
704
|
12.2%
|
11.6%
|
0.6%
|
|
|
2,343
|
|
2,090
|
12.1%
|
15.7%
|
-3.6%
|
WW
|
|
3,084
|
|
2,614
|
18.0%
|
17.8%
|
0.2%
|
|
|
9,032
|
|
7,631
|
18.4%
|
19.4%
|
-1.0%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,222
|
|
1,117
|
9.4%
|
9.4%
|
-
|
|
|
3,669
|
|
3,260
|
12.5%
|
12.5%
|
-
|
US Exports
(3)
|
|
255
|
|
180
|
41.7%
|
41.7%
|
-
|
|
|
673
|
|
602
|
11.8%
|
11.8%
|
-
|
Intl
|
|
306
|
|
316
|
-3.2%
|
-2.9%
|
-0.3%
|
|
|
1,000
|
|
1,019
|
-1.9%
|
3.4%
|
-5.3%
|
WW
|
|
1,783
|
|
1,613
|
10.5%
|
10.6%
|
-0.1%
|
|
|
5,342
|
|
4,881
|
9.4%
|
10.5%
|
-1.1%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
256
|
|
199
|
28.6%
|
28.6%
|
-
|
|
|
716
|
|
526
|
36.1%
|
36.1%
|
-
|
Intl
|
|
225
|
|
181
|
24.3%
|
20.6%
|
3.7%
|
|
|
603
|
|
462
|
30.5%
|
31.3%
|
-0.8%
|
WW
|
|
481
|
|
380
|
26.6%
|
24.8%
|
1.8%
|
|
|
1,319
|
|
988
|
33.5%
|
33.9%
|
-0.4%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
561
|
|
414
|
35.5%
|
35.5%
|
-
|
|
|
1,631
|
|
1,153
|
41.5%
|
41.5%
|
-
|
Intl
|
|
253
|
|
199
|
27.1%
|
27.8%
|
-0.7%
|
|
|
722
|
|
579
|
24.7%
|
27.2%
|
-2.5%
|
WW
|
|
814
|
|
613
|
32.8%
|
33.0%
|
-0.2%
|
|
|
2,353
|
|
1,732
|
35.9%
|
36.7%
|
-0.8%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
6
|
|
8
|
-25.0%
|
-22.6%
|
-2.4%
|
|
|
18
|
|
30
|
-40.0%
|
-32.9%
|
-7.1%
|
WW
|
|
6
|
|
8
|
-25.0%
|
-22.6%
|
-2.4%
|
|
|
18
|
|
30
|
-40.0%
|
-32.9%
|
-7.1%
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
387
|
|
379
|
2.1%
|
2.1%
|
-
|
|
|
1,107
|
|
1,172
|
-5.5%
|
-5.5%
|
-
|
Intl
|
|
455
|
|
469
|
-3.0%
|
-2.2%
|
-0.8%
|
|
|
1,340
|
|
1,683
|
-20.4%
|
-18.5%
|
-1.9%
|
WW
|
|
842
|
|
848
|
-0.7%
|
-0.3%
|
-0.4%
|
|
|
2,447
|
|
2,855
|
-14.3%
|
-13.2%
|
-1.1%
|
EDURANT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
13
|
|
11
|
18.2%
|
18.2%
|
-
|
|
|
38
|
|
29
|
31.0%
|
31.0%
|
-
|
Intl
|
|
136
|
|
100
|
36.0%
|
35.4%
|
0.6%
|
|
|
370
|
|
274
|
35.0%
|
35.2%
|
-0.2%
|
WW
|
|
149
|
|
111
|
34.2%
|
33.7%
|
0.5%
|
|
|
408
|
|
303
|
34.7%
|
34.9%
|
-0.2%
|
OLYSIO /
SOVRIAD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
13
|
|
26
|
-50.0%
|
-50.0%
|
-
|
|
|
50
|
|
174
|
-71.3%
|
-71.3%
|
-
|
Intl
|
|
8
|
|
53
|
-84.9%
|
-85.7%
|
0.8%
|
|
|
46
|
|
403
|
-88.6%
|
-88.2%
|
-0.4%
|
WW
|
|
21
|
|
79
|
-73.4%
|
-73.9%
|
0.5%
|
|
|
96
|
|
577
|
-83.4%
|
-83.1%
|
-0.3%
|
PREZISTA / PREZCOBIX
/ REZOLSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
310
|
|
285
|
8.8%
|
8.8%
|
-
|
|
|
860
|
|
777
|
10.7%
|
10.7%
|
-
|
Intl
|
|
183
|
|
183
|
0.0%
|
2.0%
|
-2.0%
|
|
|
544
|
|
566
|
-3.9%
|
-1.1%
|
-2.8%
|
WW
|
|
493
|
|
468
|
5.3%
|
6.1%
|
-0.8%
|
|
|
1,404
|
|
1,343
|
4.5%
|
5.7%
|
-1.2%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
51
|
|
57
|
-10.5%
|
-10.5%
|
-
|
|
|
159
|
|
192
|
-17.2%
|
-17.2%
|
-
|
Intl
|
|
128
|
|
133
|
-3.8%
|
-3.0%
|
-0.8%
|
|
|
380
|
|
440
|
-13.6%
|
-10.6%
|
-3.0%
|
WW
|
|
179
|
|
190
|
-5.8%
|
-5.2%
|
-0.6%
|
|
|
539
|
|
632
|
-14.7%
|
-12.6%
|
-2.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
622
|
|
655
|
-5.0%
|
-5.0%
|
-
|
|
|
1,997
|
|
2,098
|
-4.8%
|
-4.8%
|
-
|
Intl
|
|
842
|
|
821
|
2.6%
|
0.0%
|
2.6%
|
|
|
2,618
|
|
2,560
|
2.3%
|
3.5%
|
-1.2%
|
WW
|
|
1,464
|
|
1,476
|
-0.8%
|
-2.2%
|
1.4%
|
|
|
4,615
|
|
4,658
|
-0.9%
|
-0.2%
|
-0.7%
|
CONCERTA /
METHYLPHENIDATE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
102
|
|
89
|
14.6%
|
14.6%
|
-
|
|
|
365
|
|
317
|
15.1%
|
15.1%
|
-
|
Intl
|
|
88
|
|
89
|
-1.1%
|
-2.5%
|
1.4%
|
|
|
294
|
|
291
|
1.0%
|
4.4%
|
-3.4%
|
WW
|
|
190
|
|
178
|
6.7%
|
6.0%
|
0.7%
|
|
|
659
|
|
608
|
8.4%
|
10.0%
|
-1.6%
|
INVEGA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
28
|
|
82
|
-65.9%
|
-65.9%
|
-
|
|
|
70
|
|
281
|
-75.1%
|
-75.1%
|
-
|
Intl
|
|
59
|
|
57
|
3.5%
|
-1.0%
|
4.5%
|
|
|
185
|
|
179
|
3.4%
|
2.7%
|
0.7%
|
WW
|
|
87
|
|
139
|
-37.4%
|
-39.2%
|
1.8%
|
|
|
255
|
|
460
|
-44.6%
|
-44.9%
|
0.3%
|
INVEGA SUSTENNA /
XEPLION / INVEGA TRINZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
339
|
|
277
|
22.4%
|
22.4%
|
-
|
|
|
983
|
|
758
|
29.7%
|
29.7%
|
-
|
Intl
|
|
217
|
|
182
|
19.2%
|
18.8%
|
0.4%
|
|
|
646
|
|
548
|
17.9%
|
19.8%
|
-1.9%
|
WW
|
|
556
|
|
459
|
21.1%
|
20.9%
|
0.2%
|
|
|
1,629
|
|
1,306
|
24.7%
|
25.5%
|
-0.8%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
94
|
|
103
|
-8.7%
|
-8.7%
|
-
|
|
|
289
|
|
306
|
-5.6%
|
-5.6%
|
-
|
Intl
|
|
128
|
|
132
|
-3.0%
|
-3.9%
|
0.9%
|
|
|
394
|
|
430
|
-8.4%
|
-7.1%
|
-1.3%
|
WW
|
|
222
|
|
235
|
-5.5%
|
-6.0%
|
0.5%
|
|
|
683
|
|
736
|
-7.2%
|
-6.4%
|
-0.8%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
59
|
|
104
|
-43.3%
|
-43.3%
|
-
|
|
|
290
|
|
436
|
-33.5%
|
-33.5%
|
-
|
Intl
|
|
350
|
|
361
|
-3.0%
|
-7.3%
|
4.3%
|
|
|
1,099
|
|
1,112
|
-1.2%
|
-0.6%
|
-0.6%
|
WW
|
|
409
|
|
465
|
-12.0%
|
-15.3%
|
3.3%
|
|
|
1,389
|
|
1,548
|
-10.3%
|
-9.9%
|
-0.4%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
622
|
|
394
|
57.9%
|
57.9%
|
-
|
|
|
1,740
|
|
1,090
|
59.6%
|
59.6%
|
-
|
Intl
|
|
895
|
|
776
|
15.3%
|
15.4%
|
-0.1%
|
|
|
2,605
|
|
2,332
|
11.7%
|
14.1%
|
-2.4%
|
WW
|
|
1,517
|
|
1,170
|
29.7%
|
29.7%
|
0.0%
|
|
|
4,345
|
|
3,422
|
27.0%
|
28.7%
|
-1.7%
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
179
|
|
98
|
82.7%
|
82.7%
|
-
|
|
|
455
|
|
253
|
79.8%
|
79.8%
|
-
|
Intl
|
|
170
|
|
86
|
97.7%
|
*
|
**
|
|
|
450
|
|
201
|
*
|
*
|
**
|
WW
|
|
349
|
|
184
|
89.7%
|
92.1%
|
-2.4%
|
|
|
905
|
|
454
|
99.3%
|
*
|
**
|
VELCADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
304
|
|
329
|
-7.6%
|
-7.4%
|
-0.2%
|
|
|
950
|
|
1,012
|
-6.1%
|
-3.7%
|
-2.4%
|
WW
|
|
304
|
|
329
|
-7.6%
|
-7.4%
|
-0.2%
|
|
|
950
|
|
1,012
|
-6.1%
|
-3.7%
|
-2.4%
|
ZYTIGA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
282
|
|
276
|
2.2%
|
2.2%
|
-
|
|
|
840
|
|
784
|
7.1%
|
7.1%
|
-
|
Intl
|
|
300
|
|
272
|
10.3%
|
8.5%
|
1.8%
|
|
|
901
|
|
866
|
4.0%
|
5.4%
|
-1.4%
|
WW
|
|
582
|
|
548
|
6.2%
|
5.3%
|
0.9%
|
|
|
1,741
|
|
1,650
|
5.5%
|
6.3%
|
-0.8%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
161
|
|
20
|
*
|
*
|
-
|
|
|
445
|
|
53
|
*
|
*
|
-
|
Intl
|
|
121
|
|
89
|
36.0%
|
36.6%
|
-0.6%
|
|
|
304
|
|
253
|
20.2%
|
23.0%
|
-2.8%
|
WW
|
|
282
|
|
109
|
*
|
*
|
**
|
|
|
749
|
|
306
|
*
|
*
|
**
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,117
|
|
1,171
|
-4.6%
|
-4.6%
|
-
|
|
|
3,590
|
|
3,522
|
1.9%
|
1.9%
|
-
|
Intl
|
|
376
|
|
415
|
-9.4%
|
-7.4%
|
-2.0%
|
|
|
1,203
|
|
1,278
|
-5.9%
|
-1.5%
|
-4.4%
|
WW
|
|
1,493
|
|
1,586
|
-5.9%
|
-5.4%
|
-0.5%
|
|
|
4,793
|
|
4,800
|
-0.1%
|
1.1%
|
-1.2%
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
529
|
|
461
|
14.8%
|
14.8%
|
-
|
|
|
1,690
|
|
1,374
|
23.0%
|
23.0%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
529
|
|
461
|
14.8%
|
14.8%
|
-
|
|
|
1,690
|
|
1,374
|
23.0%
|
23.0%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
294
|
|
322
|
-8.7%
|
-8.7%
|
-
|
|
|
939
|
|
890
|
5.5%
|
5.5%
|
-
|
Intl
|
|
34
|
|
18
|
88.9%
|
94.3%
|
-5.4%
|
|
|
97
|
|
46
|
*
|
*
|
**
|
WW
|
|
328
|
|
340
|
-3.5%
|
-3.2%
|
-0.3%
|
|
|
1,036
|
|
936
|
10.7%
|
11.3%
|
-0.6%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
168
|
|
177
|
-5.1%
|
-5.1%
|
-
|
|
|
581
|
|
519
|
11.9%
|
11.9%
|
-
|
Intl
|
|
82
|
|
86
|
-4.7%
|
-4.7%
|
0.0%
|
|
|
265
|
|
289
|
-8.3%
|
-5.5%
|
-2.8%
|
WW
|
|
250
|
|
263
|
-4.9%
|
-4.9%
|
0.0%
|
|
|
846
|
|
808
|
4.7%
|
5.7%
|
-1.0%
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
126
|
|
211
|
-40.3%
|
-40.3%
|
-
|
|
|
380
|
|
739
|
-48.6%
|
-48.6%
|
-
|
Intl
|
|
260
|
|
311
|
-16.4%
|
-14.1%
|
-2.3%
|
|
|
841
|
|
943
|
-10.8%
|
-6.3%
|
-4.5%
|
WW
|
|
386
|
|
522
|
-26.1%
|
-24.7%
|
-1.4%
|
|
|
1,221
|
|
1,682
|
-27.4%
|
-24.9%
|
-2.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
5,042
|
|
4,509
|
11.8%
|
11.8%
|
-
|
|
|
15,123
|
|
13,423
|
12.7%
|
12.7%
|
-
|
Intl
|
|
3,358
|
|
3,185
|
5.4%
|
5.0%
|
0.4%
|
|
|
10,109
|
|
9,943
|
1.7%
|
4.2%
|
-2.5%
|
WW
|
|
$
8,400
|
|
7,694
|
9.2%
|
9.0%
|
0.2%
|
|
|
$
25,232
|
|
23,366
|
8.0%
|
9.1%
|
-1.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
MEDICAL DEVICES
SEGMENT (2) (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDIOVASCULAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
235
|
|
239
|
-1.7%
|
-1.7%
|
-
|
|
|
$
701
|
|
702
|
-0.1%
|
-0.1%
|
-
|
Intl
|
|
216
|
|
285
|
-24.2%
|
-26.8%
|
2.6%
|
|
|
663
|
|
895
|
-25.9%
|
-25.6%
|
-0.3%
|
WW
|
|
451
|
|
524
|
-13.9%
|
-15.3%
|
1.4%
|
|
|
1,364
|
|
1,597
|
-14.6%
|
-14.4%
|
-0.2%
|
DIABETES
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
191
|
|
205
|
-6.8%
|
-6.8%
|
-
|
|
|
548
|
|
631
|
-13.2%
|
-13.2%
|
-
|
Intl
|
|
236
|
|
265
|
-10.9%
|
-11.2%
|
0.3%
|
|
|
779
|
|
817
|
-4.7%
|
-2.2%
|
-2.5%
|
WW
|
|
427
|
|
470
|
-9.1%
|
-9.2%
|
0.1%
|
|
|
1,327
|
|
1,448
|
-8.4%
|
-7.0%
|
-1.4%
|
DIAGNOSTICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
7
|
|
16
|
-56.3%
|
-55.8%
|
-0.5%
|
|
|
66
|
|
62
|
6.5%
|
21.1%
|
-14.6%
|
WW
|
|
7
|
|
16
|
-56.3%
|
-55.8%
|
-0.5%
|
|
|
66
|
|
62
|
6.5%
|
21.1%
|
-14.6%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,343
|
|
1,312
|
2.4%
|
2.4%
|
-
|
|
|
4,099
|
|
3,942
|
4.0%
|
4.0%
|
-
|
Intl
|
|
908
|
|
869
|
4.5%
|
4.5%
|
0.0%
|
|
|
2,848
|
|
2,897
|
-1.7%
|
0.9%
|
-2.6%
|
WW
|
|
2,251
|
|
2,181
|
3.2%
|
3.2%
|
0.0%
|
|
|
6,947
|
|
6,839
|
1.6%
|
2.7%
|
-1.1%
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
190
|
|
185
|
2.7%
|
2.7%
|
-
|
|
|
590
|
|
568
|
3.9%
|
3.9%
|
-
|
Intl
|
|
130
|
|
124
|
4.8%
|
6.4%
|
-1.6%
|
|
|
421
|
|
410
|
2.7%
|
6.5%
|
-3.8%
|
WW
|
|
320
|
|
309
|
3.6%
|
4.2%
|
-0.6%
|
|
|
1,011
|
|
978
|
3.4%
|
5.0%
|
-1.6%
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
223
|
|
214
|
4.2%
|
4.2%
|
-
|
|
|
696
|
|
662
|
5.1%
|
5.1%
|
-
|
Intl
|
|
132
|
|
129
|
2.3%
|
4.0%
|
-1.7%
|
|
|
433
|
|
429
|
0.9%
|
4.3%
|
-3.4%
|
WW
|
|
355
|
|
343
|
3.5%
|
4.1%
|
-0.6%
|
|
|
1,129
|
|
1,091
|
3.5%
|
4.8%
|
-1.3%
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
389
|
|
368
|
5.7%
|
5.7%
|
-
|
|
|
1,151
|
|
1,083
|
6.3%
|
6.3%
|
-
|
Intl
|
|
248
|
|
239
|
3.8%
|
3.1%
|
0.7%
|
|
|
764
|
|
801
|
-4.6%
|
-2.1%
|
-2.5%
|
WW
|
|
637
|
|
607
|
4.9%
|
4.6%
|
0.3%
|
|
|
1,915
|
|
1,884
|
1.6%
|
2.7%
|
-1.1%
|
SPINE &
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
541
|
|
545
|
-0.7%
|
-0.7%
|
-
|
|
|
1,662
|
|
1,629
|
2.0%
|
2.0%
|
-
|
Intl
|
|
398
|
|
377
|
5.6%
|
5.0%
|
0.6%
|
|
|
1,230
|
|
1,257
|
-2.1%
|
0.0%
|
-2.1%
|
WW
|
|
939
|
|
922
|
1.8%
|
1.6%
|
0.2%
|
|
|
2,892
|
|
2,886
|
0.2%
|
1.1%
|
-0.9%
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,002
|
|
987
|
1.5%
|
1.5%
|
-
|
|
|
3,003
|
|
2,947
|
1.9%
|
1.9%
|
-
|
Intl
|
|
1,282
|
|
1,233
|
4.0%
|
3.9%
|
0.1%
|
|
|
3,906
|
|
3,857
|
1.3%
|
4.3%
|
-3.0%
|
WW
|
|
2,284
|
|
2,220
|
2.9%
|
2.9%
|
0.0%
|
|
|
6,909
|
|
6,804
|
1.5%
|
3.2%
|
-1.7%
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
390
|
|
357
|
9.2%
|
9.2%
|
-
|
|
|
1,131
|
|
1,046
|
8.1%
|
8.1%
|
-
|
Intl
|
|
494
|
|
438
|
12.8%
|
13.0%
|
-0.2%
|
|
|
1,478
|
|
1,359
|
8.8%
|
11.9%
|
-3.1%
|
WW
|
|
884
|
|
795
|
11.2%
|
11.3%
|
-0.1%
|
|
|
2,609
|
|
2,405
|
8.5%
|
10.3%
|
-1.8%
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
414
|
|
427
|
-3.0%
|
-3.0%
|
-
|
|
|
1,254
|
|
1,272
|
-1.4%
|
-1.4%
|
-
|
Intl
|
|
649
|
|
656
|
-1.1%
|
-1.1%
|
0.0%
|
|
|
2,006
|
|
2,063
|
-2.8%
|
0.0%
|
-2.8%
|
WW
|
|
1,063
|
|
1,083
|
-1.8%
|
-1.8%
|
0.0%
|
|
|
3,260
|
|
3,335
|
-2.2%
|
-0.5%
|
-1.7%
|
SPECIALTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
198
|
|
203
|
-2.5%
|
-2.5%
|
-
|
|
|
618
|
|
629
|
-1.7%
|
-1.7%
|
-
|
Intl
|
|
139
|
|
139
|
0.0%
|
-1.2%
|
1.2%
|
|
|
422
|
|
435
|
-3.0%
|
0.3%
|
-3.3%
|
WW
|
|
337
|
|
342
|
-1.5%
|
-2.0%
|
0.5%
|
|
|
1,040
|
|
1,064
|
-2.3%
|
-1.0%
|
-1.3%
|
VISION
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
277
|
|
262
|
5.7%
|
5.7%
|
-
|
|
|
767
|
|
758
|
1.2%
|
1.2%
|
-
|
Intl
|
|
462
|
|
421
|
9.7%
|
5.3%
|
4.4%
|
|
|
1,297
|
|
1,202
|
7.9%
|
7.7%
|
0.2%
|
WW
|
|
739
|
|
683
|
8.2%
|
5.5%
|
2.7%
|
|
|
2,064
|
|
1,960
|
5.3%
|
5.2%
|
0.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,048
|
|
3,005
|
1.4%
|
1.4%
|
-
|
|
|
9,118
|
|
8,980
|
1.5%
|
1.5%
|
-
|
Intl
|
|
3,111
|
|
3,089
|
0.7%
|
-0.2%
|
0.9%
|
|
|
9,559
|
|
9,730
|
-1.8%
|
0.5%
|
-2.3%
|
WW
|
|
$
6,159
|
|
6,094
|
1.1%
|
0.7%
|
0.4%
|
|
|
$
18,677
|
|
18,710
|
-0.2%
|
1.0%
|
-1.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100%
|
|
|
|
|
|
|
|
** Not
meaningful
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
(3) Reported as U.S.
sales
|
|
|
|
|
|
|
|
(4) Prior year
amounts have been reclassified to conform to current year product
disclosure
|
|
|
|
|
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2016-third-quarter-results-300346521.html
SOURCE Johnson & Johnson